ClinicalTrials.gg
TerminatedNCT01904253Updated Sep 5, 2024

A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy

A Phase 2 interventional study of TAS-102 and Amrubicin (Japan) in Small Cell Lung Cancer (SCLC), sponsored by Taiho Oncology, Inc.. Terminated at 23 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-05.

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Why this study was terminated
The preliminary data does not suggest any safety signal, but an ad hoc interim analysis showed an imbalance of PFS between the two arms

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies in Small Cell Lung Carcinoma with a site in Italy — 25 open to participants now, 39 under way, 18 of them phase 3. Small Cell Lung Carcinoma · Italy.

Enrollment
80th of 85
18 · median 225
Started
2013
the only one that year
Phase 2
28 of 90
5 open now
Registered
20th of 90
by date

Among the 90 studies in Small Cell Lung Carcinoma with a site in Italy, this one is the 80th largest by enrollment of the 85 interventional ones that give a count, is the only one that started in 2013, is one of 28 in phase 2, and was the 20th registered.

Small Cell Lung Carcinoma

1,302 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

25 of the 90 studies in Small Cell Lung Carcinoma with a site in Italy are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Small Cell Lung Carcinoma with a site in Italy, or all of them as a file.
02

Study summary

The purpose of this trial is to compare the effects of TAS-102 with either amrubicin or topotecan (drugs used in Small Cell Lung Cancer) on lung cancer to find out the effects on survival, how much time may pass without disease progression, and the safety of TAS-102.

Read the detailed description

This is a multicenter, open-label, two-arm, randomized Phase 2 study of TAS-102 versus Investigator's choice of therapy in patients requiring second-line chemotherapy for SCLC refractory or sensitive to first-line platinum-based chemotherapy. Investigator's choice of therapy is defined as second-line chemotherapy with IV topotecan (Europe/Japan) or IV amrubicin (Japan). Patients will be stratified by response to first-line platinum-based chemotherapy (sensitive vs refractory). Sensitive patients are defined as patients who did not progress within 90 days after the last dose, and refractory patients are defined as patients who never responded or who responded but had radiologic progression \< 90 days after the last dose.

03

Conditions studied

  • Small Cell Lung Cancer (SCLC)

Keywords

  • Second line Small Cell Lung Cancer, (SCLC), Refractory or Sensitive to First line Platinum based chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has provided written
  2. Is ≥18 years of age for patients enrolled in Europe; or ≥20 years of age for patients enrolled in Japan
  3. Has definitive or cytologically confirmed SCLC (limited or extensive disease)
  4. Has progressed or had recurrence within 30 days prior to randomization
  5. Has at least one , as defined by criteria version 1.1
  6. performance status of 0, 1, or 2
  7. Is able to take medications orally
  8. Has adequate organ function (bone marrow, kidney and liver)
  9. Women of must have a negative pregnancy test and must agree to adequate if conception is possible. Males must agree to adequate birth control.

Exclusion criteria

Exclusion Criteria:

  1. Has cerebral (unless metastases have been treated and controlled, metastases have been stable for at least 2-months post-intervention, and patient is not receiving treatment)
  2. Certain serious illnesses or medical condition(s)
  3. Has had certain other recent treatment e.g. major surgery, anticancer therapy, extended field radiation, received agent, within the specified time frames prior to study drug administration
  4. Has received TAS-102
  5. Has unresolved toxicity of greater than or equal to Grade 2 attributed to any prior therapies
  6. Is a pregnant or lactating female
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    TAS-102

    Drug: TAS-102

  • Active comparator
    Investigator Choice of Amrubicin or Topotecan

    Investigator Choice of Amrubicin (Japan only) or Topotecan (Europe and Japan)

    Drug: Amrubicin (Japan) · Drug: Topotecan (Japan/Europe)

Interventions

  • DrugTAS-102

    35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.

  • Patients will receive treatment administered according to the country-specific approved prescribing information

    Also known as: Calsed

  • DrugTopotecan (Japan/Europe)

    Drug page: Topotecan

    Patients will receive treatment administered according to the country-specific approved prescribing information

    Also known as: Hycamptin, Hycamtin

06

What researchers measure

Primary outcomes

  1. Progression-free survival

    Tumor assessments will be performed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 every 6 weeks during study treatment, and every 8 weeks after treatment is completed. Tumor assessments will be performed from Day 1, Cycle 1 until radiologic progression develops or the start of new anticancer treatment, for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met.

    Time frame: Every 6 weeks from the start of study treatment (Day 1, Cycle 1). Tumor assessments will be performed until radiologic progression develops or the start of new anticancer treatment.

Secondary outcomes

  1. Overall survival

    Time frame: Survival status will be collected at 8-week intervals until death, for up to 12 months after the first dose of study medication for the last patient randomized or until the target number of events (deaths) is met, whichever is later.

  2. Safety monitoring including adverse events, vital signs, and laboratory assessments

    Standard safety monitoring will be performed and adverse events will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03

    Time frame: Through 30 days following last administration of study medication or until initiation of new anticancer treatment

07

Study locations

23 sites
  • Klinikum Mannheim GmbH Universitaetsklinikum
    Mannheim, Baden-Württemberg, Germany
  • Lungenklinik Heckeshorn- HELIOS Kliniken GmbH
    Berlin, Germany
  • LungenClinic Grosshansdorf
    Grosshansdorf, Germany
  • Klinikum Koeln-Merheim
    Koplin, Germany
  • St. Hildegardis-Krankenhaus- Katholisches Klinikum Mainz
    Mainz, Germany
  • LMU-Campus Innenstadt
    Muenchen, Germany
  • Azienda Ospedaliero-Universitaria S. Luigi Gonzaga
    Orbassano, Turin, Italy
  • IRCCS Centro di Riferimento Oncologico di Aviano, Divisione Oncologia Medica A
    Aviano, Italy
  • Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari
    Bari, Italy
  • Azienda Ospedaliera Univ. Policlinico Gaspare Rodolico
    Catania, Italy
  • Azienda Ospedaliera Instituti Ospitalieri di Cremona
    Cremona, Italy
  • Azienda Ospedaliera Universitaria Careggi
    Firenze, Italy
  • IEO Istituto Europeo di Oncologia
    Milano, Italy
  • Azienda Ospedaliera San Gerardo U.O Oncologia Medica
    Monza, Italy
  • Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia
    Reggio Emilia, Italy
  • A.O.V.V. Ospedale Eugenio Morelli-Sondalo
    Sondalo, Italy
  • National Cancer Center Hospital East
    Chiba, 277-8577, Japan
  • National Kyushi Cancer Center
    Fukuoka, 811-1395, Japan
  • Hyogo Cancer Center
    Hyogo, 673-8588, Japan
  • Saitama Cancer Center
    Saitama, 362-0806, Japan
  • Shizuoka Cancer Center
    Shizuoka, 411-8777, Japan
  • Nippon Medical School Hospital
    Tokyo, 113-8603, Japan
  • Cancer Institute Hospital of Japanese Foundation for Cancer Research
    Tokyo, 135-8550, Japan
08

References and documents

Publications

  • Scagliotti G, Nishio M, Satouchi M, Valmadre G, Niho S, Galetta D, Cortinovis D, Benedetti F, Yoshihara E, Makris L, Inoue A, Kubota K. A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy. Lung Cancer. 2016 Oct;100:20-23. doi: 10.1016/j.lungcan.2016.06.023. Epub 2016 Jun 27. PubMed 27597276 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2013
First posted
Jul 22, 2013
Start
Jul 2013
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Last update
Sep 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01904253
Responsible party
Sponsor
First posted
Jul 22, 2013
Start date
Jul 2013
Primary completion
Jun 2014
Completion
Jun 2014
Last update
Sep 5, 2024

Study contacts

Giorgio Scagliotti, MD
principal investigator · University of Turin San Luigi Hospital
Kaoru Kubota, MD, PhD
principal investigator · Nippon Medical School Hospital Cancer Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion